Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Mussetti

Showing results (51-60 of 100) with videos related to

Pageof 10
Sort By:
Cancer Medicine|May 1, 2021
Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphomaGloria Iacoboni, Guillermo Villacampa, Nuria Martinez-Cibrian, et al.
Expert Opinion on Biological Therapy|May 17, 2017
New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?Francesca Patriarca, Luisa Giaccone, Francesco Onida, et al.
Future Oncology (London, England)|August 12, 2024
Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS studyJuan Martin-Liberal, Elena Garralda, Jesús García-Donas, et al.
Bone Marrow Transplantation|June 24, 2024
Post-transplant cyclophosphamide compared to sirolimus/tacrolimus in reduced intensity conditioning transplants for patients with lymphoid malignanciesMaria Laura Fox, Irene García-Cadenas, Victor Navarro, et al.
Cancers|December 30, 2025
Complications of Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-A Prospective Study on Behalf of the EBMT Transplant Complications Working PartyAgnieszka Tomaszewska, Grzegorz W Basak, Christophe Peczynski, et al.
British Journal of Haematology|February 12, 2026
Treosulfan/fludarabine versus thiotepa/busulfan/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post-transplant cyclophosphamide era: A GETH-TC studyMarta Peña, Lorenzo Lazzari, Diego F Martínez, et al.
Cancer Reports (Hoboken, N.J.)|March 3, 2021
The direct and indirect effects of COVID-19 pandemic in a real-life hematological settingMaria Condom, Alberto Mussetti, Clara Maluquer, et al.
Transplantation and Cellular Therapy|April 29, 2026
Real-World Validation of the Transplant Conditioning Intensity (TCI) Score in Allogeneic Hematopoietic Cell Transplantation: A Spanish Multicenter Study on behalf of GETH-TCAnnalisa Paviglianiti, Estefania Perez Lopez, Alejandro Avendaño, et al.
Blood Advances|February 12, 2021
Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donorsMichael R Grunwald, Mei-Jie Zhang, Hany Elmariah, et al.
Bone Marrow Transplantation|October 1, 2025
Patient selection and treatment outcomes over time in patients with large B-cell lymphoma receiving car T-cell therapyAnna Torrent, Mireia Morgades, Gloria Iacoboni, et al.
Pageof 10

Showing results (51-60 of 100) with videos related to

Sort By:
Pageof 10
Cancer Medicine|May 1, 2021
Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphomaGloria Iacoboni, Guillermo Villacampa, Nuria Martinez-Cibrian, et al.
Expert Opinion on Biological Therapy|May 17, 2017
New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?Francesca Patriarca, Luisa Giaccone, Francesco Onida, et al.
Future Oncology (London, England)|August 12, 2024
Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS studyJuan Martin-Liberal, Elena Garralda, Jesús García-Donas, et al.
Bone Marrow Transplantation|June 24, 2024
Post-transplant cyclophosphamide compared to sirolimus/tacrolimus in reduced intensity conditioning transplants for patients with lymphoid malignanciesMaria Laura Fox, Irene García-Cadenas, Victor Navarro, et al.
Cancers|December 30, 2025
Complications of Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-A Prospective Study on Behalf of the EBMT Transplant Complications Working PartyAgnieszka Tomaszewska, Grzegorz W Basak, Christophe Peczynski, et al.
British Journal of Haematology|February 12, 2026
Treosulfan/fludarabine versus thiotepa/busulfan/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post-transplant cyclophosphamide era: A GETH-TC studyMarta Peña, Lorenzo Lazzari, Diego F Martínez, et al.
Cancer Reports (Hoboken, N.J.)|March 3, 2021
The direct and indirect effects of COVID-19 pandemic in a real-life hematological settingMaria Condom, Alberto Mussetti, Clara Maluquer, et al.
Transplantation and Cellular Therapy|April 29, 2026
Real-World Validation of the Transplant Conditioning Intensity (TCI) Score in Allogeneic Hematopoietic Cell Transplantation: A Spanish Multicenter Study on behalf of GETH-TCAnnalisa Paviglianiti, Estefania Perez Lopez, Alejandro Avendaño, et al.
Blood Advances|February 12, 2021
Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donorsMichael R Grunwald, Mei-Jie Zhang, Hany Elmariah, et al.
Bone Marrow Transplantation|October 1, 2025
Patient selection and treatment outcomes over time in patients with large B-cell lymphoma receiving car T-cell therapyAnna Torrent, Mireia Morgades, Gloria Iacoboni, et al.
Pageof 10